PARP inhibitors are currently used in breast and ovarian cancer therapies [2, 50, 51] and considered in clinical studies for the treatment of other frequently diagnosed tumor types (e.g., brain, colon, lung, and prostate [7, 41–47]). Here, PARP1 is linked to ovarian carcinoma.